Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
P/E ratio for Ocugen, Inc. (OCGN)
P/E ratio as of 2023: -2.23
According to Ocugen, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.23. At the end of 2022 the company had a P/E ratio of -3.58.
P/E ratio history for Ocugen, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.23 |
| 2022 | -3.58 |
| 2021 | -15.20 |
| 2020 | -9.08 |
| 2019 | -0.34 |
| 2018 | -0.38 |
| 2017 | -1.76 |
| 2016 | -1.47 |
| 2015 | -1.45 |
| 2014 | -0.74 |
| 2013 | -5.83 |
| 2012 | -8.85 |